Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
|Articles|March 9, 2020
SECO 2020 attendee, Angela Driver-Scott, comments on COVID-19
Author(s)Brooke Henson, Editor
Advertisement
Angela Driver-Scott, Alcon research associate scientist, is attending her first SECO conference this year. She shares her goals for the conference as well as her thoughts on the Coronavirus Disease 2019 (COVID-19).
Advertisement
Related to this article
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.
Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.
Kwaku Osei, OD, PhD, FAAO, discussed patient-reported outcomes with a senofilcon C (Johnson & Johnson; Acuvue Vita), reusable lens, with the majority of wearers rating comfort, vision, and handling favorably.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Understanding the gene therapy landscape for retinitis pigmentosa
2
Epioxa epi-on cross-linking holds keratoconus gains at 3 years
3
AAOpt 2026: Evaluating the comfort and usability of Acuvue Vita contact lenses
4
Independent OD practices net 31% of revenue, IDOC benchmarks show
5